[
    {
        "subject": "Adherence",
        "data": {
            "description": "Extent to which a person's behaviour, taking medication,  corresponds with a health care providers reccomendation",
            "keywords": [
                "relapse",
                "therapy",
                "cost",
                "Teriflunomide",
                "RMS",
                "daily"
            ]
        }
    },
    {
        "subject": "ADME",
        "data": {
            "description": "absorption, distribution, metabolism, and excretion",
            "keywords": [
                "therapy ",
                "pharmacokinetic",
                "genome",
                "effects",
                "interruption"
            ]
        }
    },
    {
        "subject": "Administration",
        "data": {
            "description": "Inject into a vein or into an IV line",
            "keywords": [
                "inject",
                "adherence",
                "untreated",
                "autoinjector",
                "device"
            ]
        }
    },
    {
        "subject": "AEs - autoimmunity",
        "data": {
            "description": "Immune system mistakes and attacks the body's own tissues, organs",
            "keywords": [
                "efficacy",
                "thyroid",
                "placebo"
            ]
        }
    },
    {
        "subject": "AEs - Infections",
        "data": {
            "description": "The invasion and growth of germs in the body",
            "keywords": [
                "treatment",
                "placebo",
                "immunity",
                "PML",
                "CNS",
                "NAT",
                "KPS"
            ]
        }
    },
    {
        "subject": "AEs - ISRs/IARs",
        "data": {
            "description": "gradual re-narrowing of a stented coronary artery lesion due to arterial damage",
            "keywords": [
                "QoL",
                "anti-CD52",
                "antibody",
                "CD20",
                "mAB"
            ]
        }
    },
    {
        "subject": "AEs - lymphopenia",
        "data": {
            "description": "A disorder in which your blood doesn't have enough white blood cells called lymphocytes",
            "keywords": [
                "antibodies",
                "immune system",
                "interferon",
                "BG-12",
                "Oral",
                "multiple-ascending-dose",
                "ponesimod"
            ]
        }
    },
    {
        "subject": "AEs - malignancy",
        "data": {
            "description": "The tendency of a medical condition to become progressively worse",
            "keywords": [
                "antibodies",
                "imaging",
                "safety",
                "postmarketing",
                "RRMS",
                "AEs",
                "interim "
            ]
        }
    },
    {
        "subject": "AEs - systemic effects",
        "data": {
            "description": "Effects occurring in tissues distant from the site of contact between the body and medical device",
            "keywords": [
                "therapy",
                "adherence",
                "reduction",
                "Mitoxantrone",
                "cardiotoxicity",
                "LVEF"
            ]
        }
    },
    {
        "subject": "Comparative efficacy",
        "data": {
            "description": "Research that identifies what clinical and public health interventions work best for improving health.",
            "keywords": [
                "review",
                "incidence",
                "parenteral",
                "ALT",
                "IFNbeta-1a",
                "Glatiramer",
                "ARR"
            ]
        }
    },
    {
        "subject": "Cost Effectiveness",
        "data": {
            "description": "Examine both the costs and health outcomes of one or more interventions",
            "keywords": [
                "treatment",
                "doses",
                "data",
                "subcutaneous",
                "natalizumab"
            ]
        }
    },
    {
        "subject": "Diagnosis and assessment",
        "data": {
            "description": "the process of determining which disease or condition explains a person's symptoms and signs",
            "keywords": [
                "alemtuzumab",
                "MRSI",
                "RNFL",
                "OCT",
                "Alemtuzumab",
                "CD52"
            ]
        }
    },
    {
        "subject": "Discontinuations",
        "data": {
            "description": "the ceasing of a medication treatment for a patient by either the clinician or the patient themself",
            "keywords": [
                "diagnosis",
                "BG-12",
                "safety profile",
                "AEs",
                "placebo"
            ]
        }
    },
    {
        "subject": "Dose",
        "data": {
            "description": "a quantity of medicine prescribed to be taken at one time",
            "keywords": [
                "dose",
                "dosage",
                "mg",
                "treatment",
                "PRISMS",
                "Subcutaneous"
            ]
        }
    },
    {
        "subject": "Drug interactions",
        "data": {
            "description": "A reaction between two (or more) drugs or between a drug and a food",
            "keywords": [
                "dose",
                "gene",
                "infusion",
                "AUClast",
                "model based approach",
                "Fingolimod "
            ]
        }
    },
    {
        "subject": "Effects on clinical relapses",
        "data": {
            "description": "return of a disease or the signs and symptoms of a disease after a period of improvement",
            "keywords": [
                "DMD",
                "tolerability",
                "natalizumab",
                "reduced",
                "IFNB-1b",
                "GA"
            ]
        }
    },
    {
        "subject": "Effects on cognition",
        "data": {
            "description": "Effect of early initiation of therapy",
            "keywords": [
                "CIS",
                "subcutaneous",
                "infusions",
                "TYSABRI",
                "infusions",
                "DemTect"
            ]
        }
    },
    {
        "subject": "Effects on disability progression",
        "data": {
            "description": "Effects on disability progression",
            "keywords": [
                "subcutaneous",
                "natalizumab",
                "relapse",
                "routine",
                "efficacy"
            ]
        }
    },
    {
        "subject": "Effects on disease progression/activity",
        "data": {
            "description": "Effects on disease progression/activity",
            "keywords": [
                "PRISMS",
                "proportion",
                "PML",
                "MS",
                "tablets"
            ]
        }
    },
    {
        "subject": "Effects on mortality",
        "data": {
            "description": "Effects on mortality",
            "keywords": [
                "effects",
                "beta-1b",
                "duration",
                "assesment",
                "efficacy"
            ]
        }
    },
    {
        "subject": "Effects on MRI activity/outcomes",
        "data": {
            "description": "Measure the small changes in blood flow that occur with brain activity.",
            "keywords": [
                "influence",
                "effectiveness",
                "symptoms",
                "EAE",
                "ARBs",
                "PreCISe",
                "interfero beta",
                "placebo"
            ]
        }
    },
    {
        "subject": "Effects on psychological measures",
        "data": {
            "description": "Effects on psychological measures",
            "keywords": [
                "GA",
                "once-daily",
                "Fingolimod",
                "observation",
                "remit"
            ]
        }
    },
    {
        "subject": "Effects on QoL and functional outcomes",
        "data": {
            "description": "Patient's ability to enjoy normal life activities",
            "keywords": [
                "relapse",
                "cognition",
                "fatigue",
                "progression",
                "pivotal",
                "SENTINEL"
            ]
        }
    },
    {
        "subject": "Effects on sensory, motor and visual symptoms",
        "data": {
            "description": "Effects on sensory, motor and visual symptoms",
            "keywords": [
                "MM",
                "difficulty",
                "pain",
                "interferon",
                "mitoxantrone"
            ]
        }
    },
    {
        "subject": "Epidemiology",
        "data": {
            "description": "Epidemiology",
            "keywords": [
                "DMT",
                "segregation",
                "background",
                "randomized",
                "dysfunction"
            ]
        }
    },
    {
        "subject": "Gene expression",
        "data": {
            "description": "process by which the instructions in our DNA are converted into a functional product",
            "keywords": [
                "interferon",
                "microRNAs",
                "Laquinimod",
                "PBMC",
                "immunomodulator",
                "samples"
            ]
        }
    },
    {
        "subject": "General adverse events",
        "data": {
            "description": "event in which care resulted in an undesirable clinical outcome",
            "keywords": [
                "teriflunomide",
                "treatment",
                "doses",
                "RMS",
                "pain",
                "GA"
            ]
        }
    },
    {
        "subject": "General safety profile",
        "data": {
            "description": "Chemistry, pharmacology, therapeutic effects, and adverse effects of an administered drug",
            "keywords": [
                "relapse",
                "ULN",
                "parenteral",
                "therapy",
                "birth defect",
                "delay"
            ]
        }
    },
    {
        "subject": "Health-care resource utilisation",
        "data": {
            "description": "quantification or description of the use of services by persons for the purpose of preventing and curing health problems",
            "keywords": [
                "IV",
                "corticosteroids",
                "sequelae",
                "relapse",
                "EDSS",
                "dimethyl fumarate",
                "MS"
            ]
        }
    },
    {
        "subject": "Immunogenicity/NAbs and effects on clinical outcomes",
        "data": {
            "description": "The ability of cells/tissues to provoke an immune response",
            "keywords": [
                "IFNbeta",
                "NAbs",
                "NKT",
                "PBMC",
                "intramuscularly"
            ]
        }
    },
    {
        "subject": "indiacation for use",
        "data": {
            "description": "The Indications and Usage section must state that the drug is indicated for the treatment, prevention, mitigation, cure, or diagnosis of a recognized disease or condition",
            "keywords": [
                "therapy",
                "TEMSO",
                "oral disease modifier",
                "oral disease-modifying therapy",
                "DMT",
                "cholestyramine",
                "Interferon-beta-1b",
                "Interferon-beta-1a",
                "Gilenya",
                "Fingolimod",
                "has been an approved",
                "long-lasting suppression of disease activity"
            ]
        }
    },
    {
        "subject": "SAEs",
        "data": {
            "description": "any untoward medical occurrence that at any dose. Results in death. Is life-threatening",
            "keywords": [
                "Teriflunomide",
                "Injection-site pain",
                "injection-site reactions",
                "ISP",
                "ISR",
                "lymphopenia",
                "ONO-4641",
                "double-blind trial",
                "blind trial",
                "Adverse events",
                "hypertension"
            ]
        }
    },
    {
        "subject": "Unmet needs",
        "data": {
            "description": "a condition for which there exists no. satisfactory method of diagnosis, prevention or treatment in the Union. or, even if such a method exists, in relation to which the medicinal",
            "keywords": [
                "fingolimod",
                "TYSABRI",
                "STRATA",
                "Fingolimod",
                "FTY720",
                "Natalizumab",
                "identify",
                "glatiramer acetate",
                "GA",
                "treatment"
            ]
        }
    }
]